Helius Medical Technologies announced the expansion of its clinical development program for the broadening of the labeling of its marketed PoNS device to include patients recovering from stroke with the participation of Shepherd Center, under the direction of Michael Yochelson, M.D., MBA, FAAN, FAAPMR, Chief Medical Officer. Participating to the Company-sponsored single-arm study, Shepherd Center joins Brooks Rehabilitation as a third clinical site to the overall registrational program. The study aims to evaluate the potential benefit of PoNS Therapy in treating gait and balance deficits in chronic stroke survivors. Shepherd Center has been an impactful participant in the PoNS Therapeutic Experience Program, a Company-sponsored outcome research clinical trial designed to evaluate the impact of subjects’ adherence to PoNS Therapy in people with multiple sclerosis, a trial led by Deborah Backus, PT, Ph.D., FACRM, Vice President of Research and Innovation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSDT:
- Helius Medical files to sell Class A common stock, warrants, no amount given
- Shares of Helius Medical pop 10% after PoNS Therapy partnership with Lovell
- Helius Medical expands reach of PoNS Therapy with Lovel Government Services
- Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
- Helius Medical reports Q4 EPS ($1.47), consensus ($3.77)
